Aviceda Therapeutics has launched biotech financing in 2025 with a $207.5m raise to advance its lead drug for geographic atrophy, a sight-threatening disease, into pivotal trials.
The Series C round, co-led by Omega Funds and TCGX, will support the ongoing phase 2/3 SIGLEC trial of AVD-104 for geographic atrophy linked to age-related macular degeneration.
The trial is expected to deliver results in the second half of the year, with funding also allocated to a phase 3 programme if progress stays on track.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
The funding round also saw participation from investment firms including Enavate Sciences, Jeito Capital, Blue Owl Healthcare Opportunities, Longitude Capital, OrbiMed, Logos Capital, Marshall Wace, Catalio Capital Management, and Digitalis Ventures.
Source: Pharmaphorum
Can’t stop reading? Read more
Investors target $5bn to launch global basketball league competing with the NBA
A consortium of investors, led by Maverick Carter and advised by UBS Group AG and Evercore, is...
KKR taps Goldman Sachs to explore partial stake sale in Philippine fintech Maya
KKR enlisted Goldman Sachs to manage the potential partial sale of its stake in Maya, a leading...
Trump names private equity CEO to lead Federal Housing Finance Agency
President-elect Donald Trump nominated Bill Pulte, CEO of private equity firm Pulte Capital...